BioWorld

Nov. 23, 2005

High Number Of Dropouts Spoil Oxytrex Phase III Trial

Shares in Pain Therapeutics Inc. lost nearly 20% of their value on news that a Phase III study of Oxytrex was inadequate due to patient dropouts, meaning another trial is in order. (BioWorld Today) Read More

Point Therapeutics Offering Gets $22.2M For Talabostat

Antitrust Hearing Could Lead To Changes In Merger Review

Nurel, Diamyd Combine GAD Technologies Through Merger

Holiday Notice

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...